Skip to main content
Real-world evidence for COSELA
Navbar Image
Real-world evidence for COSELA
This site is intended only for US healthcare professionals.

Real-world evidence for COSELA

Lower incidence of chemotherapy dose reductions and delays with COSELA in a real-world study2

CHEMOTHERAPY DOSE REDUCTIONS AND DELAYSa

  • Fewer occurrences of chemotherapy dose reductions and delays in patients receiving COSELA based on real-world data2

Infusion interruption data from Cosela Prescribing Informationb

  • Infusion interruptions due to an adverse reaction occurred in 4.1% of patients
See the Study Design
a
Dose reduction and treatment delay were evaluated in the iKnowMed-based COSELA and non-COSELA studies. Such outcomes were not available in the Florida Cancer Specialists and Research Institute or Integra Connect studies due to data limitations.2
b
Dose reductions and delays observed in real-world studies may be influenced by multiple factors (e.g., clinical practice patterns, patient characteristics, or treatment decisions) and are not solely attributable to adverse events.

Real-world evidence is observational and may be subject to limitations, including lack of randomization.